Research/Development stage company, creating novel embryonic stem cell therapy for Insuling dependent Diabetes.
| Website | http://www.novocell.com |
| Revenue | $8.6 million |
| Employees | 3 (0 on RocketReach) |
| Address | 3550 General Atomics Ct, San Diego, California 92121, US |
| Phone | +55 19 3454-6257 |
| Industry | Biotechnology, Pharmaceuticals, Healthcare |
| Keywords | Stem Cell Therapy, Diabetes Treatment, Regenerative Medicine, Cell Therapy, Insulin Dependent Diabetes, Type 1 Diabetes, Novel Therapies, Biotechnology, Pharmaceutical Research, Drug Development, Clinical Trials, Therapeutic Development, Cellular Therapies, Research And Development, Life Sciences, Biomedical Research, Healthcare, Medical Research, Disease Treatment |
| Competitors | Genentech, Amgen, Regeneron, Vertex Pharmaceuticals, Illumina, Lengo Therapeutics, Intellia Therapeutics, Inc., CRISPR Therapeutics, Editas Medicine, Sangamo Therapeutics, Inc. +32 more (view full list) |
| SIC | SIC Code 28 Companies, SIC Code 283 Companies |
| NAICS | NAICS Code 32 Companies, NAICS Code 3254 Companies, NAICS Code 325 Companies |
Looking for a particular Novocell employee's phone or email?
The Novocell annual revenue was $8.6 million in 2026.
Novocell is based in San Diego, California.
The NAICS codes for Novocell are [32, 3254, 325].
The SIC codes for Novocell are [28, 283].